Miglitol attenuates non‐alcoholic steatohepatitis in diabetic patients

Aim Postprandial hyperglycemia is frequently accompanied by non‐alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Although α‐glucosidase inhibitors (αGIs) can slow glucose absorption from the intestine and suppress the surge of circulating glucose concentration after meals, it remain...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2018-12, Vol.48 (13), p.1092-1098
Main Authors: Komatsu, Michiharu, Tanaka, Naoki, Kimura, Takefumi, Fujimori, Naoyuki, Sano, Kenji, Horiuchi, Akira, Sugiura, Ayumi, Yamazaki, Tomoo, Shibata, Soichiro, Joshita, Satoru, Umemura, Takeji, Matsumoto, Akihiro, Tanaka, Eiji
Format: Article
Language:English
Subjects:
Alanine
Alanine transaminase
alpha‐glucosidase inhibitor
Balloon treatment
Biopsy
Body mass index
Clinical trials
Diabetes mellitus
Fatty liver
Fibrosis
Hemoglobin
Hyperglycemia
Inflammation
Intestine
Liver diseases
lobular inflammation
Miglitol
non‐alcoholic steatohepatitis
Patients
Steatosis
α-Glucosidase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Postprandial hyperglycemia is frequently accompanied by non‐alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). Although α‐glucosidase inhibitors (αGIs) can slow glucose absorption from the intestine and suppress the surge of circulating glucose concentration after meals, it remains unclear whether αGIs are also beneficial for NASH. The aim of this prospective study was to examine the efficacy and safety of miglitol, a typical αGI, for NASH. Methods Seventeen patients with histologically confirmed NASH and hemoglobin A1c (HbA1c) >6.5% were treated with miglitol (150 mg/day) for 12 months. The changes in clinical parameters and liver histology were analyzed. Results All patients completed the 12‐month miglitol treatment course with no severe adverse events. The treatment significantly decreased body mass index, serum alanine aminotransferase levels, and HbA1c (all P 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13223